Asia Pacific in-vitro diagnostics market revenue was US$ 15.5 billion in 2022 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 4.67% to reach a valuation of US$ 23.01 billion by 2031.
Tests called in vitro diagnostics (IVDs) can identify illnesses, disorders, and infections. In vitro, which literally means "in glass," refers to the fact that these tests are frequently carried out in test tubes. Tests conducted in vitro might be carried out at clinics, hospitals, or even individuals' homes. Small, portable tests and sophisticated laboratory equipment can all use to conduct the testing themselves. They enable medical professionals to diagnose patients and pursue the most effective treatments.
Factors Affecting the Growth of the Global Market
Impact Analysis of COVID-19
Diagnostics have developed quickly, regulatory approvals have been expedited, and distribution has been stepped up in a number of regions to assist stop the COVID-19 virus's spread. The identification of infectious diseases has always required the use of in vitro diagnostics (IVDs). Demand for COVID-19 diagnostic tests, such as RT-PCR tests, antigen tests, and antibody tests, has increased owing to the outbreak, which has further fueled the expansion. There are numerous molecular and immunoassays available today to identify COVID-19. The current state of affairs calls for high-quality diagnostics that deliver quicker and more precise test findings.
Country Analysis
Japan dominated the market with a share of more than 28%. With a solid regulatory environment, cutting-edge healthcare infrastructure, and high levels of healthcare spending, the Japanese IVD industry is well established. The Japanese government has aggressively encouraged the advancement and implementation of novel IVD technologies, which has sped up the market's expansion.
The Japanese IVD market is growing due to the rising prevalence of chronic disorders like diabetes, cardiovascular disease, and cancer. Thus, this has increased the demand in Japan for rapid and precise diagnosis. Additionally, Japan's aging population has helped the market expand owing to the rising demand for healthcare services, particularly diagnostic tests.
Another important factor driving the Japanese in-vitro diagnostics market is the uptake of point-of-care (POC) testing. POC testing offers prompt and precise results, which is very useful in urgent and critical care circumstances.
Prominent Companies
The leading companies profiled in the Asia Pacific in-vitro diagnostics market are:
Segmentation Outline
The Asia Pacific in-vitro diagnostics market segmentation focuses on Test Type, Product, Usability, Application, End-User, and Country.
By Test Type
By Product
By Usability
By Application
By End-User
By Country
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
4 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE MODEL
4.4 VALUE CHAIN ANALYSIS
5 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY TEST TYPE
5.1 OVERVIEW
5.2 CLINICAL CHEMISTRY
5.3 MOLECULAR DIAGNOSTICS
5.4 IMMUNO-DIAGNOSTICS
5.5 HAEMATOLOGY
5.6 OTHER TEST TYPES
6 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 INSTRUMENTS
6.3 REAGENTS
6.4 OTHER PRODUCTS
7 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY USABILITY
7.1 OVERVIEW
7.2 DISPOSABLE IVD DEVICES
7.3 REUSABLE IVD DEVICES
8 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 INFECTIOUS DISEASES
8.3 DIABETES
8.4 CANCER/ONCOLOGY
8.5 CARDIOLOGY
8.6 AUTOIMMUNE DISEASES
8.7 NEPHROLOGY
8.8 OTHER APPLICATIONS
9 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY END-USER
9.1 OVERVIEW
9.2 DIAGNOSTIC LABORATORIES
9.3 HOSPITALS AND CLINICS
9.4 OTHER END USERS
10 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET, BY COUNTRY
10.1 OVERVIEW
10.2 INDIA
10.3 JAPAN
10.4 SOUTH KOREA
10.5 AUSTRALIA & NEW ZEALAND
10.6 ASEAN
10.7 REST OF ASIA PACIFIC
11 GLOBAL ASIA PACIFIC IN-VITRO DIAGNOSTICS MARKET COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPANY MARKET RANKING
11.3 KEY DEVELOPMENT STRATEGIES
12 COMPANY PROFILES
12.1 BIOMÉRIEUX SA
12.1.1 OVERVIEW
12.1.2 FINANCIAL PERFORMANCE
12.1.3 PRODUCT OUTLOOK
12.1.4 KEY DEVELOPMENTS
12.2 DANAHER (BECKMAN COULTER)
12.2.1 OVERVIEW
12.2.2 FINANCIAL PERFORMANCE
12.2.3 PRODUCT OUTLOOK
12.2.4 KEY DEVELOPMENTS
12.3 F HOFFMANN-LA ROCHE LTD.
12.3.1 OVERVIEW
12.3.2 FINANCIAL PERFORMANCE
12.3.3 PRODUCT OUTLOOK
12.3.4 KEY DEVELOPMENTS
12.4 BECTON, DICKINSON, AND COMPANY
12.4.1 OVERVIEW
12.4.2 FINANCIAL PERFORMANCE
12.4.3 PRODUCT OUTLOOK
12.4.4 KEY DEVELOPMENTS
12.5 BIO-RAD LABORATORIES INC.
12.5.1 OVERVIEW
12.5.2 FINANCIAL PERFORMANCE
12.5.3 PRODUCT OUTLOOK
12.5.4 KEY DEVELOPMENTS
12.6 ABBOTT LABORATORIES
12.6.1 OVERVIEW
12.6.2 FINANCIAL PERFORMANCE
12.6.3 PRODUCT OUTLOOK
12.6.4 KEY DEVELOPMENTS
12.7 ARKRAY INC.
12.7.1 OVERVIEW
12.7.2 FINANCIAL PERFORMANCE
12.7.3 PRODUCT OUTLOOK
12.7.4 KEY DEVELOPMENTS
12.8. SYSMEX CORPORATION
12.8.1 OVERVIEW
12.8.2 FINANCIAL PERFORMANCE
12.8.3 PRODUCT OUTLOOK
12.8.4 KEY DEVELOPMENTS
12.9 ORTHO CLINICAL DIAGNOSTICS
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
12.10 SIEMENS HEALTHINEERS
12.10.1 OVERVIEW
12.10.2 FINANCIAL PERFORMANCE
12.10.3 PRODUCT OUTLOOK
12.10.4 KEY DEVELOPMENTS
12.11 THERMO FISCHER SCIENTIFIC INC.
12.11.1 OVERVIEW
12.11.2 FINANCIAL PERFORMANCE
12.11.3 PRODUCT OUTLOOK
12.11.4 KEY DEVELOPMENTS
12.12 QIAGEN NV
12.12.1 OVERVIEW
12.12.2 FINANCIAL PERFORMANCE
12.12.3 PRODUCT OUTLOOK
12.12.4 KEY DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved